ArticleJACC. Case reports2025
Post SARS-CoV-2 Myocarditis: Giant Cell or MIS-A? A Misdiagnosis Leading to a Heart Transplantation.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiant cell myocarditis (GCM) and multisystem inflammatory syndrome in adults (MIS-A) with myocarditis that appears after SARS-CoV-2 infection (COVID-19) may manifest similarly. CASE SUMMARY: We describe a patient with GCM who presented with cardiogenic shock and received a misdiagnosis of MIS-A myocarditis because of a lack of giant cells identified on endomyocardial biopsy (EMB). Her cardiac function improved with combined immunosuppressive therapy, including cyclosporine, but subsequently worsened, with premature cessation of immunosuppression resulting from the misdiagnosis. The patient received a heart transplant. Pathologic examination of the explanted heart confirmed the diagnosis of necrotizing GCM. DISCUSSION: The diagnosis of GCM is challenging given the limited sensitivity of EMB. Treatment includes prolonged calcineurin-based combined immunosuppression, and early cessation of treatment can lead to fatal relapse. TAKE-HOME MESSAGE: COVID-19 may cause delayed myocarditis, and high clinical suspicion for GCM is crucial to inform appropriate management and increase the likelihood of survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.